Integrated therapy of kidney cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Longo, R ^a   D'Andrea, M R ^a   Sarmiento, R ^a   Salerno, F ^a   Gasparini, G ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Chemotherapy; Kidney cancer; Metastatic renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AXITINIB; BEVACIZUMAB; CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; GEFITINIB; IMATINIB; INFLIXIMAB; INTERFERON; INTERLEUKIN 2; LAPATINIB; MONOCLONAL ANTIBODY; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FATIGUE; FUNCTIONAL STATUS; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC REGULATION; GENETIC RISK; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SOLID TUMOR; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; DRUG DELIVERY SYSTEM; KIDNEY TUMOR; METABOLISM; METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY;

EID: 35748961731     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm244     Document Type: Conference Paper

References (78)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Zambrano NR, Lubensky IA, Merino MJ et al. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 1999; 162: 1246-1258.
3. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
4. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
5. Herman A Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704.
6. Kamura T, Sato S, Iwai K et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000; 97: 10430-10435.
7. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301.
8. Vita VT De, Hellman S, Rosemberg SA. Principles and Practice of Oncology, 7th edition. Part 3, 30, Section 1.
9. Kjaer M, Iversen P, Hvidt V et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987; 21: 285-289.
10. Master VA, Gottschalk AR, Kane C, Carroll PR. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol 2005; 174: 473-477 [Discussion 47].
11. Juusela H, Malmio K, Alfthan O, Oravisto KJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 1977; 11: 277-281.
12. Nelsen EC, Evans CP, Lara PN Jr. Renal cell carcinoma: Current status and emerging therapies. Cancer Treat Rev 2007.
13. Fojo AT, Shen DW, Mickley LA at al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922-1927.
14. Warner E, Tobe SW, Andrulis IL et al. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma, Am J Clin Oncol 1995; 18: 251-256.
15. Samuels BL, Hollis DR, Rosner GL et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A cancer and leukemia group B study. Clin Cancer Res 1997; 3: 1977-1984.
16. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Onool 2000; 27: 177-186.
17. Lilleby W, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol 2005; 23: 175-179.
18. Rini BI, Vogelzang NJ, Dumas MC et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419-2426.
19. Stadler WM, Halabi S, Rini B et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107: 1273-1279.
20. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42.
21. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology 2002; 16: 4-10.
22. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-913.
23. Fyfe GA, Fisher RI, Rosenberg SA et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14: 2410-2411.
24. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132.
25. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867.
26. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 1999; 353: 14-17.
27. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005: CD001425.
28. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin OnGol 2000; 27: 187-193.
29. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon affa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.
30. Bardos JI. Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioassays 2004; 26: 262-269.
31. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions. Clin Cancer Res 2007; 13(4): 1098-1106.
32. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003: 427-434.
33. Bukowski R, Kabbinavar F, Figlin RA et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol 2006 (Suppl)): (Abstr 4523).
34. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the multi-kinase inhibitor BAY 43-9006 in patients with advanced renal cell carcinoma. Eur J Cancer 2005; 3 (Suppl): 226.
35. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
36. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
37. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
38. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
39. Hudes GR, Carducci M, Tomczak P et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24 (Suppl): 930S (Abstr LBA4).
40. Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 99-101.
41. Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 341-345.
42. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003-3015.
43. Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006; 24 (Suppl): 217S (Abstr 4502).
44. Vuky J, Fotoohi M, Isacson C et al. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 21: 416 (Abstr 1672).
45. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
46. Eisen T, Bukoswki RM, Staehler M et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC0: Impact of crossover on survival). J Clin Oncol 2006; 24 (Suppl): 223S (Abstr 4524).
47. Escudier B, Szczylik C, Demkow T et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24: 217S (Abstr 4501).
48. De Mulder PH, Roigas J, Gillessen S et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl): 223S (Abstr 4529).
49. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235-246.
50. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014.
51. Frost P, Moatamed F, Hoang B et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004; 104: 4181-4187.
52. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
53. Smith JW, Ko Y-J, Dutcher J et al. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22 (Suppl): 385S (Abstr 4513).
54. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alpha as a comparative treatment for clinical trias of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
55. Yang JC. Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 2004; 10: 6367S-6370S.
56. Hurwitz HI, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
57. Rini B, Rixe O, Bukowksi R et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23 (Suppl): 380S (Abstr 4509).
58. Amato RJ, Misellati A, Khan M et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2006; 24 (Suppl): 224S (Abstr 4530).
59. Dupont J, Camastra D, Gordon M et al. Phase I study of VEGF Trap in patients with solid tumors and lymphoma. Proc Am Soc Clin Oncol 2003; 22: 194 (Abstr 776).
60. Maisey NR, Hall K, Lee C et al. Infliximab: A phase II trial of the tumour necrosis factor (TNFα) monoclonal antibody in patients with advanced renal cell cancer (RCC). J Clin Oncol 2004: 22S (Abstr 4514).
61. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
62. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ. Physiologically based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 2003; 30: 185-219.
63. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520-11539.
64. Gemmill RM, Zhou M, Costa L et al. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer 2005; 92: 2266-2277.
65. Kim SJ, Uehara H, Karashima T et al. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003; 9: 1200-1210.
66. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB2-neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol 1997; 151: 1523-1530.
67. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560.
68. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-1556.
69. Rini BI, George DJ, Michaelson MD et al. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Ann Oncol 2006; 17: 144S (Abstr 4380).
70. Tamaskar I, Shaheen P, Wood L et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol 2006; 24: 240S (Abstr 4597).
71. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
72. Jacobsen J, Grankvist K, Rasmuson T et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297-302.
73. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-147.
74. DePrimo SE, Bello CL, Smeraglia J et al. Soluble protein biomarkers of pharmacodynamic activity of the multitargeted kinase inhibitor SU11248 in patients with metastatic renal cell carcinoma. Proc Am Assoc Cancer Res 2005; 46: 464.
75. Rini BI, Jaeger E, Weinberg V et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006; 98: 756.
76. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007; 13 (2 Pt 2): 764S-769S.
77. Gasparini G, Gion M. Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper end points. Cancer J 2000; 6: 117-131.
78. Gasparini G, Longo R, Fanelli M et al. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 2005; 23: 1295-1311.